Breaking News, Collaborations & Alliances

Cambrex Manufactures Transgenic Protein

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Cambrex Corp. subsidiary Cambrex Bio Science Hopkinton, Inc. has entered a contract to produce clinical trial quantities of Merrimack Pharmaceuticals’ lead product MM-093, a recombinant version of human alpha-fetoprotein (hAFP). The material is expected to be used in Merrimack’s research to assess the potential of MM-093 to treat multiple autoimmune diseases, including rheumatoid arthritis, multiple sclerosis, psoriasis and others. Cambrex has completed several batches of MM-093 and ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters